Pioneering the development of proprietary molecules designed to neutralize and remove harmful agents from the body through a groundbreaking sequestration-based approach.
Reversal Therapeutics, Inc. is a preclinical stage biopharmaceutical company pioneering the development of proprietary molecules designed to neutralize and remove a wide range of agents from the body through a revolutionary sequestration mode of action.
Reversal is dedicated to saving lives and accelerating patient recovery by harnessing the Company’s broad-spectrum sequestration technology to reverse the effects of neuromuscular blocking agents and other various drugs across areas of high need.
Co-Founder & Chairman
Eric, trained as a corporate attorney, is a serial entrepreneur leading breakthrough developments in pharma/healthcare.
CEO
Dr. Anthony Schwartz is an entrepreneur with almost 20 years of experience in biotechnology-based startup companies.
Co-Founder & Consultant, Chief Scientific Advisor
Professor Lyle Isaacs is the inventor of sulfated pillararenes and is currently a Professor of Chemistry and Biochemistry at the University of Maryland.
Chief Development Officer
Adam has a PhD in Toxicology and 22 years of pharmaceutical industry experience spanning all phases of clinical and nonclinical drug development.
Executive Vice President and General Counsel
Prior to his current role, Jay spent 21 years with the U.S. Department of Justice, with the majority as an Assistant United States Attorney.
Synthetic Medical Chemist
Dr. Formen received his Ph.D. in organic chemistry from Georgetown University, where he has published over 10 studies in esteemed peer reviewed journals.
Advisor, NMB Reversal
Head of the Department of Anesthesia at Massachusetts General Hospital, Harvard Medical School.
Advisor, Drugs of Abuse
Director of the Laboratory of Preclinical Pharmacology at McLean Hospital and an Associate Professor of Psychiatry at Harvard Medical School.
Advisor
Chief Communications Officer and Senior Vice President of UnitedHealth Group.
U.S. Army (Retired), Advisor
CEO of THE 5Ps, LLC; Served over 35 years in U.S. Army and was the Deputy Director and Program Executive Officer of the TRICARE Management Activity, Office of the Assistant Secretary of Defense (Health Affairs).
Advisor
Chairman of BFM Seaward LLC; Former CEO of the U.S. Naval Academy Alumni Association and Foundation for over 13 years.
Reversal Therapeutics’ innovative lead drug offers a cost-effective and efficient solution for reversing neuromuscular blockade, effectively binding to and reversing all three major neuromuscular blocking agents (NMBAs)—vecuronium, rocuronium, and cisatracurium. Designed with an efficient synthesis process, Reversal’s breakthrough compound has the potential to provide a reliable and accessible option for rapid NMBA reversal, ensuring improved patient safety and streamlined recovery in clinical settings .
Reversal Therapeutics’ product pipeline focuses on the synthesis and development of three promising drug candidates aimed at effective NMBA reversal. All synthesis occurs in the company’s laboratory. To validate efficacy and safety of Reversal’s compounds, collaboration with partners at prestigious medical schools ensures rigorous in vivo testing. These partnerships accelerates the translation of innovative molecules from the lab to clinical application, advancing cutting-edge solutions for patient care.
Stay up to date with the latest breakthroughs in sequestration-based therapies, drug detoxification, and cutting-edge biotech research.
March 2025
UMD spinout Reversal Therapeutics Inc. has joined the Mtech Ventures incubator.
read more
28 Jan 2025
MaxQ and Sugammadex Enhance Recovery From Rocuronium- and Vecuronium-Mediated Neuromuscular Blockade With Similar Effects in Isoflurane-Anesthetized Rats.
Cotten JF, Isaacs L. Pillar[6]
doi: 10.1213/ANE.0000000000007336. Epub ahead of print. PMID: 39874945.
Issue 32, 2024
MaxQ functions as an in vivo sequestrant for rocuronium and vecuronium
Zhang, W.; Bazan-Bergamino, E. A.; Doan, A.; Zhang, X.; Isaacs, L. Pillar[6]
13 April 2023
MaxQ: A potent supramolecular host for in vivo sequestration of methamphetamine and fentanyl
Brockett, A. T.; Xue, W.; King, D.; Deng, C.; Zhai, C.; Shuster, M.; Rastogi, S.; Briken, V.; Roesch, M. R.; Isaacs, L. Pillar[6]